Targeted nanoparticle delivery overcomes off-target immunostimulatory effects of oligonucleotides and improves therapeutic efficacy in chronic lymphocytic leukemia. - Wikidata - wikimedia - TriplyDB

Targeted nanoparticle delivery overcomes off-target immunostimulatory effects of oligonucleotides and improves therapeutic efficacy in chronic lymphocytic leukemia.

Targeted nanoparticle delivery overcomes off-target immunostimulatory effects of oligonucleotides and improves therapeutic efficacy in chronic lymphocytic leukemia.

http://www.wikidata.org/entity/Q36512593

about

Current understanding of interactions between nanoparticles and the immune system Nanomedicine and drug delivery strategies for treatment of inflammatory bowel disease Extracellular communication via microRNA: lipid particles have a new message Pre-clinical immunotoxicity studies of nanotechnology-formulated drugs: Challenges, considerations and strategy Antibody Therapies in Cancer.Liposomes as vaccine delivery systems: a review of the recent advances.Antisense approach to inflammatory bowel disease: prospects and challenges.Antibody-based therapeutics for the treatment of human B cell malignancies Targeted drug delivery and cross-linking induced apoptosis with anti-CD37 based dual-ligand immunoliposomes in B chronic lymphocytic leukemia cells.The non-coding transcriptome as a dynamic regulator of cancer metastasis Apoptosis inducers in chronic lymphocytic leukemia.Guiding principles in the design of ligand-targeted nanomedicines.Nanomedicines for cancer therapy: state-of-the-art and limitations to pre-clinical studies that hinder future developments.Nanomaterials for enhanced immunity as an innovative paradigm in nanomedicine.Strategy for selecting nanotechnology carriers to overcome immunological and hematological toxicities challenging clinical translation of nucleic acid-based therapeutics.Epigenetic Control of B Cell Development and B-Cell-Related Immune Disorders.Polyphosphate as a metabolic fuel in Metazoa: A foundational breakthrough invention for biomedical applications.Extracellular microRNAs in Membrane Vesicles and Non-vesicular Carriers.Injection site reactions after subcutaneous oligonucleotide therapy CD20-targeting in B-cell malignancies: novel prospects for antibodies and combination therapies.miR-181b as a therapeutic agent for chronic lymphocytic leukemia in the Eµ-TCL1 mouse model.A microfluidic method to synthesize transferrin-lipid nanoparticles loaded with siRNA LOR-1284 for therapy of acute myeloid leukemia.A novel liposomal formulation of FTY720 (fingolimod) for promising enhanced targeted delivery.Liposome-targeted delivery for highly potent drugs.Comparative analysis of metallic nanoparticles as exogenous soft tissue contrast for live in vivo micro-computed tomography imaging of avian embryonic morphogenesis.Cell type-specific delivery of short interfering RNAs by dye-functionalised theranostic nanoparticles.Vector-independent transmembrane transport of oligodeoxyribonucleotides involves p38 mitogen activated protein kinase phosphorylation.Destination Known: Targeted Drug Delivery in Atherosclerosis and Thrombosis

P2860

Q26345204-7D1E8112-CD71-472A-9894-13D0FF81A05F Q26777400-F76503B7-4D7F-41E3-865F-05111501DC54 Q27010226-BFF3BDFA-9301-4FE5-8F1B-1FF8AD2F4D3C Q28081577-FF9BE8D2-BB6B-401D-9CD3-222459119953 Q31104000-2C8BAAB7-683B-409D-987D-517FBE0E1FB1 Q34418761-C61F5956-5E43-424E-A852-5492080EA825 Q34473572-9DF44FCA-39B6-4B7C-9E60-F9998A5F096C Q36907540-9C968658-84A8-478F-9D4E-8FD58E1D35AF Q37129235-265DF0EA-3F39-458C-9141-C9E5B1BA1032 Q37705696-3725128B-A478-441B-9B0E-D6BF3AAC4AA4 Q38187815-5071D020-8084-49AE-8E59-8E7709BF057B Q38189490-AC1E9E98-ADBA-4A7A-81D3-35E3CF5EC128 Q38247299-65DC271E-1E1B-4AC8-A6ED-565703B85623 Q38418305-8B0006D7-D624-4D93-B00A-30DDA2821F43 Q38494470-561704B9-5D60-49FE-BDCD-04DFB300E9A1 Q38525405-2B710CE1-E461-4C61-A63C-4EE99946F274 Q38584191-6CB09316-964A-4CE4-B68B-36B88C67452F Q38648005-289E4ACC-F64E-4E86-A80B-4CC1D8E5AAFF Q38803235-DCC05EAE-9016-4FD4-8BA5-0F2235926458 Q38807514-8C0910C2-2062-41A3-A088-9882F15F14F2 Q38862227-72DCDFDF-993D-4B99-9288-61399197C1E4 Q38977151-38F66AFD-D7BD-4129-BA12-3583DA8D6748 Q39106527-2F37899F-64FD-4928-AA40-AF8B0600DE68 Q39171223-64442403-73B8-46C2-8D18-B7AF54472BCA Q41639959-05650B6A-312F-478A-8FB8-0502D812A7DF Q41732280-69A3DD16-20BE-447C-A83F-1FE62DED0BFE Q42659834-DD033E31-FE27-4D2C-B622-1E428DF330EB Q57342839-D076C270-5550-48CE-949E-0BD5D2C767D2

P2860

Targeted nanoparticle delivery overcomes off-target immunostimulatory effects of oligonucleotides and improves therapeutic efficacy in chronic lymphocytic leukemia.

http://www.wikidata.org/entity/Q36512593

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

2012年论文

@zh

2012年论文

@zh-cn

name

Targeted nanoparticle delivery ...... chronic lymphocytic leukemia.

@ast

Targeted nanoparticle delivery ...... chronic lymphocytic leukemia.

@en

type

label

Targeted nanoparticle delivery ...... chronic lymphocytic leukemia.

@ast

Targeted nanoparticle delivery ...... chronic lymphocytic leukemia.

@en

prefLabel

Targeted nanoparticle delivery ...... chronic lymphocytic leukemia.

@ast

Targeted nanoparticle delivery ...... chronic lymphocytic leukemia.

@en

P1433

Q36512593-3AB757BD-02B2-4D7A-AB0A-36153EEB9176

P1476

Q36512593-066E6D33-8B9F-414B-9E75-50B24732EBD5

P2093

Q36512593-1C21E56F-6CE2-4C43-A1D7-ECB938E9225B

Q36512593-1F5CC8FE-1443-45BB-AA82-AE5861862093

Q36512593-239869A8-9D5E-4E85-B025-06B5D8D99B1C

Q36512593-5153565D-10EC-4BF9-AB2B-13DE52F06134

Q36512593-60BBE3DF-30D9-4F6A-85A4-C208A34F0B58

Q36512593-844D8E5D-7288-46B5-8C3B-C31D2B294A27

Q36512593-92E60110-4FC2-4C49-BC67-1C4B69070B84

Q36512593-9F999FB7-6853-412F-8C36-972106963D9D

Q36512593-A1083922-07C8-4B20-825F-701DF95AA92C

Q36512593-A98E6415-A5BD-4C33-A913-3CCCCD2DFC6E

P2860

Q36512593-001E3BB4-E9FC-4E5C-B710-1A846A7BD248

Q36512593-02A54F63-CFE8-4B63-B77B-1DB10DCA4EC9

Q36512593-080367F9-2366-4A08-9C7D-9342DE24A8C2

Q36512593-09EFC581-1D57-409E-9591-7C7B0715760F

Q36512593-11B0344D-1D63-4244-9CFE-0C5B3BD8B638

Q36512593-34AD7C8E-45B1-4767-BF93-67AB2E69B79A

Q36512593-48C23351-8856-49FB-8111-F502573BE2F9

Q36512593-4D2A1FC5-5130-4C2F-856A-D53C12154AEF

Q36512593-59BC109D-314E-4785-A174-7BA95C446771

Q36512593-5CD9246E-8270-4C16-9454-3A3403F85303

P304

Q36512593-5BF67D91-9A10-4ED3-900D-981D7358F08C

P31

Q36512593-0AC3837A-1A3B-47B0-B86E-BD858703C002

P356

Q36512593-F69CB779-7570-4A9C-83E3-AE61AF0EA8E0

P407

Q36512593-7405317A-FD29-433C-9A17-040374971D50

P433

Q36512593-4CD1EFB6-8F52-4158-898C-EA13E3BED7FC

P478

Q36512593-383E3D9C-D469-4C50-86CB-1E153D819B37

P50

Q36512593-52567975-D20C-41FB-B162-39A9367DF781

Q36512593-AE0C9DA9-260C-40F9-9F2E-D4719226DB4F

P577

Q36512593-D5823572-9248-4EAB-88AA-9B46F5B5ECA0

P698

Q36512593-BC62EC8B-2C63-4D7A-B259-C8E9FE5DB8A9

P921

Q36512593-A0F64897-7BFD-4111-99C1-67DD29286A7C

Q36512593-B267A605-3C5C-4617-A45A-A43117DBF7EE

Q36512593-E242D372-C1EE-4F64-9686-230AB26C71A1

P932

Q36512593-6AD178EB-C6B5-48C0-BA73-C8D99456E54C

P356

BLOOD-2012-01-407742

P1433

P1476

Targeted nanoparticle delivery ...... chronic lymphocytic leukemia.

@en

P2093

Asha Ramanunni

http://www.w3.org/2001/XMLSchema#string

Bo Yu

http://www.w3.org/2001/XMLSchema#string

Carolyn Cheney

http://www.w3.org/2001/XMLSchema#string

David Jarjoura

http://www.w3.org/2001/XMLSchema#string

Kenneth K Chan

http://www.w3.org/2001/XMLSchema#string

L James Lee

http://www.w3.org/2001/XMLSchema#string

Li-Yuan Bai

http://www.w3.org/2001/XMLSchema#string

Natarajan Muthusamy

http://www.w3.org/2001/XMLSchema#string

Robert J Lee

http://www.w3.org/2001/XMLSchema#string

Sarah E M Herman

http://www.w3.org/2001/XMLSchema#string

P2860

NF- kappa B2/p100 induces Bcl-2 expression

Targeting CD37-positive lymphoid malignancies with a novel engineered small modular immunopharmaceutical

Chronic lymphocytic leukemia

The BCL-2 protein family: opposing activities that mediate cell death

Nuclear factor-kappaB in cancer development and progression

Randomized phase III trial of fludarabine plus cyclophosphamide with or without oblimersen sodium (Bcl-2 antisense) in patients with relapsed or refractory chronic lymphocytic leukemia.

Oblimersen for the treatment of patients with chronic lymphocytic leukemia.

Toll-like receptors on B-CLL cells: expression and functional consequences of their stimulation.

Toll-like receptor 9 signaling by CpG-B oligodeoxynucleotides induces an apoptotic pathway in human chronic lymphocytic leukemia B cells.

Targeting microRNAs in cancer: rationale, strategies and challenges.

P304

136-147

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1182/BLOOD-2012-01-407742

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

121

http://www.w3.org/2001/XMLSchema#string

P50

P577

2012-11-19T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23165478

http://www.w3.org/2001/XMLSchema#string

P921

P932

3538326

http://www.w3.org/2001/XMLSchema#string